Tel Aviv University
Latest From Tel Aviv University
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in July and August 2017.
Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.
Most of the current industry interest in autophagy – a mechanism cells use to degrade and remove damaged material – is centered on its role as a cancer drug target, but autophagy is also a neuroprotective mechanism. Now, a research team has shown its involvement in schizophrenia, opening the door for new drug and diagnostic development efforts.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.